Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2018 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

EGFR, MUC-1 and PD-L1 expressions in cases with triple negative breast cancer (TNBC).

Sub-category:
Adjuvant Therapy

Category:
Breast Cancer—Local/Regional/Adjuvant

Meeting:
2018 ASCO Annual Meeting

Abstract No:
e12584

Citation:
J Clin Oncol 36, 2018 (suppl; abstr e12584)

Author(s): Semra Paydas, Cem Mirili, Emine Bagir, Gulsah Seydaoglu, Ali Oğul, Mahmut Büyüksimsek, Abdullah Evren Yetisir, Bilgin Karaalioglu, Mert Tohumcuoglu; Cukurova University Faculty of Medicine, Department of Oncology, Adana, Turkey; Cukurova University Faculty of Medicine, Department of Pathology, Adana, Turkey; Cukurova University Faculty of Medicine, Department of Biostatistics And Medical Science, Adana, Turkey

Abstract Disclosures

Abstract:

Background: Immune checkpoint ligand PD-L1 and transmembrane oncogenic protein MUC-1 are upragulated in TNBC and contribute aggressive behavior of this disease. It has been shown that pharmacologic targeting of MUC-1 suppress the PD-L1 expression in cell lines. The aim of this study is to explore the association between MUC-1, PD-L1 and EGFR expressions in tumor samples and to compare them with survival times and also possible role of therapeutic targeting of these molecules Methods: MUC-1, EGFR and PD-L1 expressions were detected by immunohistochemistry in cases with TNBC. Clinical and prognostic parameters were compared with MUC-1, EGFR and PD-L1 expressions Results: 97 cases with TNBC were evaluated; 17 of them had stage I, 47 had stage II, 27 had stage III and 6 had stage IV disease. All of the cases had been treated by anthracycline and taxane containing regimens. MUC-1, EGFR and PD-L1 were detected in 34, 61 and 17 cases, respectively. PFS and OS were found to be longer in cases with EGFR expression and MUC-1 and EGFR double expressors for MUC-1 and EGFR. Table 1 shows PFS and OS times according to the EGFR, MUC-1 and PDL-1 expressions. EGFR was found to be significant in Cox regression analysis. Conclusions: EGFR was found to be the most important prognostic indicator in patients with TNBC.

Progression free survival (PFS) and overall survival (OS) according to MUC-1, EGFR and PD-L1 expression in TNBC.

Total(n)PFS
OS
Total(%)Event (n)Meanp*Meanp
MUC1
negative6364,92396,499,176112,0390.202
positive3435,18122,744132,350
EGFR
negative3637,11784,714,050*92,8890,013*
positive6162,914120,362133,890
PD-L1-tumor
negative8082,528105,6870,207116,125,121
positive1717,53125,889135,182
PD-L1-microenvironment
negative7779,427103,8070,118117,411,199
positive2020,64127,930133,500
MUC1-EGFR
Both (-)2424,71469,75077,458
Both (+)2222,85119,7730,045*131,136,025*
MUC1-PD-L1
Both (-)5556,722106,964
Both (+)1010,32130,400,250

 
Other Abstracts in this Sub-Category:

 

1. TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.

Meeting: 2018 ASCO Annual Meeting Abstract No: LBA1 First Author: Joseph A. Sparano
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

2. Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.

Meeting: 2018 ASCO Annual Meeting Abstract No: 500 First Author: Michael Gnant
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

3. Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.

Meeting: 2018 ASCO Annual Meeting Abstract No: 501 First Author: Robert E. Coleman
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

More...